Physician profile
John Berry
NPI 1144546110
$35,520.59
in general payments reported to CMS, 2019-2025
18 companies · $12K in 2025
The $12K reported for 2025 was more than what 94% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,155 · 2020: $12.95 · 2021: $133 · 2022: $1,486 · 2023: $7,812 · 2024: $13K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Education: $4,000 · Food and Beverage: $1,102 · Travel and Lodging: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,675.00 |
| Education | $4,000.00 |
| Food and Beverage | $1,101.86 |
| Travel and Lodging | $956.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $24,200.00 | 2024-2025 | |
| Intuitive Surgical, INC. | $5,456.85 | 2019-2025 | Davinci Xi, Da Vinci Surgical System, Da Vinci Sp |
| Medtronic, INC. | $2,887.51 | 2021-2024 | Ligasure, Interstim, Eea |
| Ethicon Endo-Surgery INC. | $750.00 | 2022 | |
| Applied Medical Resources Corporation | $738.43 | 2019 | |
| Olympus Corporation of The Americas | $666.74 | 2022 | |
| Davol INC. | $302.86 | 2019-2025 | Arista, Progel Applicator Spray Tips |
| Ethicon US, LLC | $162.18 | 2021-2022 | |
| Stryker Corporation | $141.26 | 2019 | |
| Atricure, INC. | $41.13 | 2025 | Atricure Cryoice Cryosphere Cryoablation System, Atricure Cryoice Cryoablation System (Cryo2) |
| Ets Wound Care LLC | $38.99 | 2024 | Mirragen Advanced Wound Matrix |
| Genentech USA, INC. | $25.00 | 2024 | Polivy, Lunsumio, Columvi |
| Astrazeneca Pharmaceuticals Lp | $21.50 | 2024 | Tagrisso |
| Daiichi Sankyo INC. | $21.07 | 2019 | |
| Stemline Therapeutics INC. | $18.99 | 2024 | Orserdu |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $16.73 | 2024 | |
| Spectrum Pharmaceuticals INC. | $16.53 | 2024 | Rolvedon |
| Morphosys, US INC. | $14.82 | 2024 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.